Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Zahariy A. Krastev"'
Autor:
Dimitrina K. Dimitrova-Dikanarova, Vladislav V. Lazarov, Radka Tafradjiiska-Hadjiolova, Ivanka I. Dimova, Nina U. Petkova, Zahariy A. Krastev
Publikováno v:
Biotechnology & Biotechnological Equipment, Vol 31, Iss 1, Pp 1-8 (2017)
The aim of this study was to investigate the possible association between serum anti-Helicobacter pylori antibodies and anti-sperm antibodies (ASA) in patients with gastroduodenal diseases caused by H. pylori, infertile patients positive for ASA and
Externí odkaz:
https://doaj.org/article/202b58db163a4956b568d692b1cb3f8c
Autor:
Nina U. Petkova, Vladislav V. Lazarov, Zahariy A. Krastev, Dimitrina Dimitrova-Dikanarova, Ivanka Dimova, Radka Tafradjiiska-Hadjiolova
Publikováno v:
Biotechnology & Biotechnological Equipment, Vol 31, Iss 1, Pp 1-8 (2017)
The aim of this study was to investigate the possible association between serum anti-Helicobacter pylori antibodies and anti-sperm antibodies (ASA) in patients with gastroduodenal diseases caused by H. pylori, infertile patients positive for ASA and
Autor:
Uma Mahadevan, Alan L. Buchman, Scott E. Plevy, Grigor M. Mechkov, Matthew Frankel, Daniel C. Baumgart, Walter Reinisch, Bruce Salzberg, Stephen B. Hanauer, Lloyd Mayer, Gert Van Assche, Zahariy A. Krastev, Stephan R. Targan, Axel Dignass, Daan W. Hommes, James N. Lowder, William J. Sandborn
Publikováno v:
Inflammatory Bowel Diseases, 16(4), 620-629
Background: Visilizumab is a humanized IgG2 monoclonal anti-CD3 antibody. We evaluated its safety and dose response in severe intravenous steroid-refractory ulcerative colitis (UC). Methods: In all, 104 patients were treated. In Stage I, 73 patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f996b7e2cd56e8c4be8953be3e87b7b8
https://hdl.handle.net/1887/109165
https://hdl.handle.net/1887/109165